Portage Biotech Inc. (PRTG)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Robert A. Kramer Ph.D. | Chief Scientific Officer | 185.89k | -- | -- |
| Mr. Alexander Pickett | CEO & Director | -- | -- | -- |
| Ms. Eun-Jae Park CPA | Chief Financial Officer | -- | -- | 1972 |
| Adam Melero | Controller | -- | -- | -- |
| Mr. Peter Molloy | Chief Executive Officer of Cyncado Therapeutics Inc. | -- | -- | -- |
Portage Biotech Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 7
Description
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; and PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors. The company also develops PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Corporate Governance
Upcoming Events
August 13, 2025 at 12:30 PM UTC - August 18, 2025 at 12:30 PM UTC
Portage Biotech Inc. Earnings Date
Recent Events
August 23, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing